Trial Profile

An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Miltefosine (Primary) ; Paromomycin (Primary) ; Sodium stibogluconate; Sodium stibogluconate
Indications Visceral leishmaniasis
Focus Therapeutic Use

20 Sep 2023 Results (n=265) of a Population pharmacokinetic model analysis using data from this trial published in the Journal of Antimicrobial Chemotherapy
27 Sep 2022 Primary endpoint has been met (Definitive Cure) , according to Results published in the Clinical Infectious Diseases
27 Sep 2022 Results published in the Clinical Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com